| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5698411 | Clinical Oncology | 2015 | 8 Pages |
Abstract
The Phoenix definition of nadir plus 2.0Â ng/ml does not allow the early identification of men destined to relapse. The initiation of salavage therapy at the earliest opportunity could potentially affect subsequent survival and an outline randomised controlled trial proposal is presented.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
D.B. McLaren, G. Kerr, A.B. Law, J.P. Brush, J. Keanie, J. Malik, W. Keough, T. Ronaldson, J. Lee, T. Kehoe,